Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 7/20 | 0.41 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | KDM5A | P29375 | 2/20 | 0.31 |
| ▸ | KDM5B | Q9UGL1 | 2/20 | 0.31 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.31 |
| ▸ | NAMPT | P43490 | 1/20 | 0.31 |
| ▸ | CPB1 | P15086 | 3/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2539194 | 0.88 | CPB2 (0.38) | CPB2SSTR4CA14KDM5AKDM5B | |
| SCHEMBL24841243 | 0.74 | SSTR4 (0.41) | CPB2SSTR4CA14KDM5AKDM5B | |
| SCHEMBL2608081 | 0.73 | CA14 (0.49) | SSTR4CA14HDAC3HDAC1HDAC2 | |
| SCHEMBL25095623 | 0.73 | KDM4E (0.34) | CPB2HDAC3HDAC1CPB1 | |
| SCHEMBL11908082 | 0.71 | KDM5A (0.37) | CPB2KDM5AKDM5BCPB1 | |
| SCHEMBL28502507 | 0.71 | CPB2 (0.32) | CPB2SSTR4 | |
| SCHEMBL10164509 | 0.71 | HCRTR1 (0.36) | CPB2SSTR4CA14HDAC3HDAC1 | |
| SCHEMBL10267170 | 0.70 | CA12 (0.43) | SSTR4CA14HDAC3HDAC1HDAC2 | |
| SCHEMBL12427151 | 0.70 | AAK1 (0.40) | CPB2 | |
| SCHEMBL34474799 | 0.69 | TDP1 (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8906852-B2 | Inhibitors of protein tyrosine kinase activity | METHYLGENE INC. (CA) | 2014-12-09 | — | — | US | disclosed |
| US-20140315801-A1 | METHODS OF TREATMENT OF CELL PROLIFERATIVE AND/OR OPHTHALMIC DISEASES, DISORDERS AND CONDITIONS USING INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | METHYLGENE INC (CA) | 2014-10-23 | — | — | US | disclosed |
| US-20110257100-A1 | Inhibitors of Protein Tyrosine Kinase Activity | METHYLGENE INC. (CA) | 2011-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257100-A1 | Inhibitors of Protein Tyrosine Kinase Activity | ERBB2, ABL1, FLT1 | CPB2 2580/4885SSTR4 1885/4885CA14 4709/4885 |
| US-20140315801-A1 | METHODS OF TREATMENT OF CELL PROLIFERATIVE AND/OR OPHTHALMIC DISEASES, DISORDERS AND CONDITIONS USING INHIBITORS OF PROTEIN TYROSINE KINASE ACTIVITY | FLT1, KDR, FLT4 | CPB2 1803/4885SSTR4 831/4885CA14 4157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.